Clinical Trial

Study of CHS-114 in Participants With Advanced Solid Tumors

Name: Study of CHS-114 in Participants With Advanced Solid Tumors — clinical trial record (NCT05635643)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Protocol Amendment History 2 changes

critical Enrollment closed, study ongoing 2026-08-13

notable Trial sites reduced: 16 -> 12 locations 2026-08-13

Trial Details

NCT Number	NCT05635643
Lead Sponsor	Coherus Oncology, Inc.
Conditions	Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Enrollment	87 participants
Start Date	2022-12-15
Primary Completion	2026-09-30 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-12